CINIE CINIE
中文 | English | Français | Русский
Home CINIE World Nuclear Fusion Nuclear Application

Search Results

Keyword:Nuclear Medicine PET

University of Tokyo and University of York Successfully Validate Positronium Ratio Imaging Principle for the First Time

University of Tokyo and University of York Successfully Validate Positronium Ratio Imaging Principle for the First Time

A research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK established a novel geometric imaging principle utilizing positron three-photon decay. Using a gamma-ray measurement system comprising scintillators and silicon photomultipliers (SiPMs), along with the existing PET radiopharmaceutical ^18F-FDG, they successfully visualized the positronium three-photon decay ratio for the first time, completing the proof-of-principle for Positronium Ratio Imaging (PRI). The findings were published in *Communications Physics*. Current clinical nuclear medicine PET examinations primarily utilize gamma rays generated from two-photon annihilation between positrons and electrons to visualize drug accumulation in the body. While this method provides quantitative information on metabolism or drug uptake, it offers limited insight into microenvironmental features such as tissue hypoxia, which are closely related to disease malignancy. In recent years, researchers have attempted to obtain additional tissue information through the average lifetime of positronium formed during positron annihilation, but this approach typically requires the introduction of special nuclides or agents, limiting its practical application.

2026-08-12

Reading Ranking

  • 1 Real-Time Perception, Full-Scope Visibility! CNNC Environmental Protection's "SMARP2.0" Leads a New Paradigm in Nuclear Power Radiation Protection
  • 2 French nuclear power sets record unavailability rate due to high temperatures and drought, one-sixth of capacity constrained
  • 3 Ikata Nuclear Power Station Reports 5 Notifiable Events in July, None Causing Radiological Environmental Impact
  • 4 ITM Receives Complete Response Letter from FDA for ¹⁷⁷Lu-edotreotide New Drug Application
  • 5 UK's MAST Upgrade sets plasma pressure record in fifth experimental campaign
  • 6 South Korea Designates Small Modular Reactors and Nuclear Fusion as Key Future Growth Technologies
  • 7 Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation
  • 8 U.S. and European Nuclear Fuel Markets Accelerate Adjustment, with Canada and Kazakhstan Remaining Leading Uranium Supply Sources
  • 9 U.S. National Nuclear Security Administration Extends Savannah River Site Management and Operating Contract to September 2027
  • 10 Huaneng Changjiang Nuclear Power Company Signs Medical Cooperation Agreement with Hainan Western Central Hospital
  • 11 U.S. nuclear energy company Holtec advances on two fronts this week: decommissioning aging nuclear plants and positioning small reactors in the southern U.S.
  • 12 South Korea and Sweden Discuss Cooperation on High-Level Waste Disposal and SMR Regulation
  • 13 Installation of STT153A Tower Crane Completed at Jiangsu Xuwei Nuclear Heating and Power Plant by CEEC
  • 14 Deep Fission Details 'One-Mile-Deep PWR' Roadmap at Canaccord Conference, Targeting First Commercial Operation by End of 2027
  • 15 Unit 3 of Japan's Ohi Nuclear Power Plant Automatically Shuts Down
CINIE

Organizing Committee of the Shenzhen Nuclear Expo

Telephone: +86 10-67808008

+86 10-68808008

Email: info@cinie.net

CINIE

Event Overview News Center Support Services Highlights Archive Contact Us

World Nuclear

China Nuclear Power News World Nuclear Power News Expert Views Nuclear Power Technology

Fusion

China Fusion World Fusion Big Science Facilities ITER Program Business & Capital

Nuclear Application

Medical Scientific Research Environmental Protection Industry Food Agriculture Security
About us | All rights reserved
CINIE All rights reserved 2026 ICP License:京ICP备12027382号-9